NRX Pharmaceuticals, Inc. (NRXP) stock
NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.15−0.04 (-1.83%)
Close on Nov 16, 2026Market cap $93.09MP/E –Yield –
NRX Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
NRX Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$19.70M. For fiscal 2025 it was -$16.15M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.15M | – |
| FY2024 | Dec 31, 2024 | -$18.50M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.44M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.68M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.58M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.02M | – |
See a number that looks wrong?